## Checklist for Submitting Requests for Revision to the *USP-NF* for New and Existing Small Molecules Monographs

This checklist can be used to prepare submission packages for new **small molecules** monographs and requests for revisions to existing **small molecules** monographs. For detailed information, consult the <u>USP Guideline for Submitting Requests for Revision to USP–NF</u>, available on our website. The information below is typically listed in the 3.2.S. for drug substances and 3.2.P. for drug products in the approved application (eCTD).

Approval Status  ☐ Finished dosage form:
- Indicate approval status (e.g., approved, OTC or OTC switch, etc.)
<ul> <li>Provide the FDA letter of approval (if available)</li> <li>Drug substance monograph:</li> </ul>
- Indicate if it has been included in an approved application
<ul> <li>Provide the ANDA number or a letter of authorization (DMF holders)</li> </ul>
<ul> <li>Application pending FDA approval:</li> <li>Supply filing letter or tentative approval letter from the FDA (if available)</li> </ul>
- For more information, see <i>Pending Monographs Guideline</i>
Monograph Content  Note: It is not a requirement to submit a draft monograph or revision written in USP–NF style.
☐ Methods/Procedures:
- Include all proposed tests and analytical procedures (see <u>Required Supporting Data</u>
section) Include brand/grade of all reagents used in the analytical procedures
☐ Shelf-life acceptance criteria
<ul><li>For revisions of an existing monograph:</li><li>Provide rationale for the proposed changes</li></ul>
- Frovide fationale for the proposed changes
Chemical Information
For the proposed article (e.g., drug substance, drug product) and each known impurity and/or degradation product, include:
☐ Chemical name(s)
☐ Chemical structure
<ul><li>☐ Molecular formula</li><li>☐ Molecular weight</li></ul>
☐ CAS no. (if known)
<u>Validation/Verification Data</u> ☐ Validation data:
- Typically applies to chromatographic procedures for Assay and Organic Impurities
tests validated per Validation of Compendial Procedures <1225> and current FDA/ICH
guidelines. □ Verification data:
<ul> <li>Include any data available for general chapter tests (e.g., Residue on Ignition, Water,</li> </ul>
Elemental Impurities, etc.).

•	Required Supporting Data
	☐ Stability data for the drug substance/product
	☐ Certificates of Analysis (COAs)
	<ul> <li>Include COAs for at least three production-scale lots/batches. If COAs are not</li> </ul>
	available, data can be submitted in a summary table or other convenient format.
	☐ Spectrophotometric procedures:
	<ul> <li>Include representative spectra (e.g., IR, UV)</li> </ul>
	☐ Chromatographic procedures:
	<ul> <li>Include representative chromatograms (e.g., standard solution, sample solution,</li> </ul>
	system suitability solution, peak identification solution, etc.)
	<ul> <li>Include the brand name and the specifications of the chromatographic column used for</li> </ul>
	the validation
	<ul> <li>Include forced degradation data to support stability-indicating procedures</li> </ul>
•	Dissolution/Disintegration/Drug release tests (if applicable)
	See Guideline on Dissolution / Drug Release / Disintegration Tests in USP Monographs
	☐ Include a copy of the product's specification, a copy of the FDA approval letter (the letter
	issued by the FDA Bioequivalence group), and results from at least three batches if
	available (any type of batch)
	☐ Include a summary of the justification for the selection of the test conditions (medium,
	apparatus, etc.)
	☐ Include the dissolution analytical method and validation report
•	Additional Requested Data
	□ Packaging and Storage:
	<ul> <li>Include packaging and storage recommendations (e.g., preserve in tight containers</li> </ul>
	and store at controlled room temperature)
	- Include special handling instructions (e.g. store under nitrogen, do not freeze, etc.)
	<ul> <li>For proposed finished dosage form monographs, include a copy of the approved</li> </ul>
	package insert
	☐ Labeling Information:
	<ul> <li>Include monograph-specific labeling requirements regarding safety and handling of the</li> </ul>
	product (e.g., must be diluted before use, must be shaken before use, indicate if it is of
	plant or animal origin, etc.)
	☐ Include a description and solubility entry (for proposed drug substance monographs)
•	Reference Standards
	☐ Indicate, in writing, the organization's ability to donate the reference standard material(s)
	to support the standard development
	<ul> <li>Typical bulk donation amounts are 250 g for API and 10-25 g for Impurities</li> </ul>
	<ul> <li>If relevant reference material cannot be provided in the estimated quantities above,</li> </ul>
	USP may need to look for an alternate source, which may delay the development of
	the standard.
	☐ For additional information, see the <u>USP Guideline for Donors of USP Reference Standard</u>
	Candidate Materials available on the USP website.